skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Triamcinolone acetonide for rare ocular manifestations of pemphigus vulgaris: a case report

Case report

(2149) Views  (664) Full article downloads

Authors: N Kozeis, S Tyradellis, E Dragiotis, et al

Published Date April 2010 Volume 2010:4 Pages 365 - 368
DOI: http://dx.doi.org/10.2147/OPTH.S8189

N Kozeis1, S Tyradellis1, E Dragiotis1, H Eleftheriadis2

1Department of Ophthalmology, Hippokration Hospital of Thessaloniki, Greece; 2Southend Hospital NHS Trusts, Westcliff-on-Sea, Essex, UK

Abstract: We present an interesting case of pemphigus vulgaris with severe and rare eye manifestations. An old lady with systemic and ocular manifestations of pemphigus vulgaris was treated with systemic corticosteroids and immunosuppressants, with no effect. Subconjunctival injection of triamcinolone acetate reduced the ocular signs and led to gradual reduction of the systemic medications.

Keywords: pemphigus vulgaris, ocular manifestations, triamcinolone acetate








Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Besifloxacin: a novel anti-infective for the treatment of bacterial conjunctivitis
Ranibizumab in the treatment of choroidal neovascularization on the border of an inferior staphyloma associated with tilted disc syndrome
Is monthly retreatment with intravitreal bevacizumab (Avastin®) necessary in neovascular age-related macular degeneration?
The comparison of clinical outcomes of endophthalmitis from fluoroquinolone-resistant and susceptible bacteria
Sequential spectral domain OCT documentation of retinal changes after branch retinal artery occlusion
Perception of risk and benefit in patient-centered communication and care
The relationship between deliberate self-harm behavior, body dissatisfaction, and suicide in adolescents: current concepts
Zinc oxide nanoparticles as selective killers of proliferating cells
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy